Genzyme beats Street

GENZ reported second quarter 2005 non-GAAP EPS of $0.57, beating the Street estimate by $0.04 and up 30% from $0.44 in the second quarter of 2004. Second quarter revenues increased 22% to $668.1 million from $549.6 million in the same quarter last year.

Second quarter sales of Cerezyme imiglucerase for Type I Gaucher's disease were $236 million, up 13% from $209.4 million in the second quarter of 2004. Sales of Renagel sevelamer for end-stage renal disease (ESRD) were $100.8 million, up 15% from $87.6 million in the prior year's quarter. Fabrazyme agalsidase beta for Fabry's disease posted second quarter sales of $74.4 million, up 50% from $49.6 million a year ago. ...